Ninety-Six - Hour Paclitaxel Infusion after Progression during Short Taxane Exposure: A Phase II Pharmacokinetic and Pharmacodynamic Study in Metastatic Breast Cancer

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1877-1884

  Seidman, Andrew D ^a   Hochhauser, Daniel ^b   Gollub, Marc ^b   Edelman, Bonnie ^b   Yao, T J ^b   Hudis, Clifford A ^b   Francis, Prudence ^b   Fennelly, David ^b   Gilewski, Theresa A ^b   Moynahan, Mary Ellen ^b   Currie, Violante ^b   Baselga, José ^b   Tong, William ^b   O'Donaghue, Mary ^b   Salvaggio, Rori ^b   Auguste, Lucienne ^b   Spriggs, David ^b   Norton, Larry ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DOCETAXEL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM EXPOSURE; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0029946928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1877     Document Type: Article

References (35)

1. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1995
2. Hainsworth J, Greco A: Paclitaxel administered by 1-hour infusion - Preliminary results of a phase I/II trial comparing two schedules. Cancer 74:1377-1382, 1994
3. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
4. Nabholtz JM, Gelmon K, Bontebal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1996 (in press)
5. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
6. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
7. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
8. Wilson WH, Berg S, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
9. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
10. Zhan Z, Kang YK, Regis J, et al: Taxol resistance: In vitro and in vivo studies in breast cancer and lymphoma. Proc Am Assoc Cancer Res 34:215, 1993 (abstr)
11. Webster L, Linsenmeyer M, Millward M, et al: Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685-1690, 1993
12. Adler LM, Herzog TJ, Williams S, et al: Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer 74:1891-1898, 1994
13. Chin A, Ramakrishnan R, Yoshimura NN, et al: Paclitaxel stability and compatibility in polyolefin containers. Ann Pharmacother 28:35-36, 1994
14. Miller AB, Hoogstraten B, Staguent M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
15. Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1987
16. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
17. Lokich J, Anderson N: Infusional cancer chemotherapy: Historical evolution and future development at The Cancer Center of Boston. Cancer Invest 13:202-226, 1995
18. Norton L: Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 12:231-249, 1985
19. Aschele A, Sobrero A, Faderan MA, et al: Novel mechanisms of resistance to 5-fluorouracil in human cancer sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992
20. Mori A, Bertoglio S, Guglielmi A, et al: Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 33:179-180, 1993
21. Deny WB, Wilson L, Jordan MA: Stoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34:2203-2211, 1995
22. Kelland LR, Abel G: Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992
23. Liebmann JE, Cook JA, Lipschultz C, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104-1109, 1993
24. Georgiadis MS, Russell E, Johnson BE, et al: Prolonging the exposure of human lung cancer cells to paclitaxel improves the cytotoxicity. Proc Am Assoc Cancer Res 35:341, 1994 (abstr)
25. Gupta RS: Taxol resistant mutants of Chinese Hamster Ovary cells: Genetic, biochemical, and cross-resistance studies. J Cell Physiol 114:137-144, 1983
26. Uziely B, Delaflor-Weiss E, Lenz HJ, et al: Paclitaxel (Taxol) in refractory breast cancer: Response correlates with low levels of mdr-1 gene expression. Proc Am Soc Clin Oncol 13:75, 1994 (abstr)
27. Roy SN, Horwitz SB: A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45:3856-3863, 1985
28. Schibler MJ, Cabral F: Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α and β-tubulin. J Cell Biol 102:1522-1531, 1986
29. Spriggs DR, Tondini C: Taxol administered as a 120 hour infusion. Invest New Drugs 10:275-278, 1992
30. Riseberg D, Cowan K, Tolcher A, et al: 96-hour paclitaxel without and with r-verapamil in patients previously treated with 3-or 24-hour paclitaxel. Proc Am Soc Clin Oncol 14:180, 1995 (abstr)
31. Chang AY, Boros L, Garrow G, Asbury R: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 22:124-127, 1995 (suppl 6)
32. Seidman AD, Weinstock N, Siegel P, et al: Outcomes analysis for patients receiving paclitaxel for metastatic breast cancer (MBC): Relationship between tumor response, quality of life, and expenditures. Proc Int Congr Chemother 6:228C, 1995 (abstr)
33. Gianni L: Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6:861-863, 1995 (editorial)
34. Seidman A: Paclitaxel: The long and short of it. Cancer J Sci Am 1:250-251, 1995 (editorial)
35. Seidman AD, Portenoy R, Yao T-J, et al: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87:1316-1322, 1995